Cynapsus Therapeutics completes C$25 million short form prospectus offering

Date Closed: 4/15/2014

Value: C$25 million

On April 15, 2014, Cynapsus Therapeutics Inc. completed a short form prospectus offering (the Offering) of units, consisting of one common share and one common share purchase warrant, for the maximum aggregate gross proceeds of C$25 million.

Cynapsus intends to use the net proceeds from the Offering to complete the U.S. clinical development of its Parkinson’s drug candidate, APL-130277. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue Parkinson’s patients from “off” episodes.

BLG acted for M Partners Inc., as agent, with a team that included Jeff Graham and David Surat.